| Current safeguards, risk mitigation, and transparency measures of large language models against the generation of health disinformation: repeated cross sectional analysis BD Menz, NM Kuderer, S Bacchi, ND Modi, B Chin-Yee, T Hu, C Rickard, ... bmj 384, 2024 | 97 | 2024 |
| Health disinformation use case highlighting the urgent need for artificial intelligence vigilance: weapons of mass disinformation BD Menz, ND Modi, MJ Sorich, AM Hopkins JAMA internal medicine 184 (1), 92-96, 2024 | 97 | 2024 |
| Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023 Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators Journal of the American College of Cardiology 86 (22), 2167-2243, 2025 | 77 | 2025 |
| The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data ND Modi, JQE Tan, A Rowland, B Koczwara, AY Abuhelwa, ... NPJ Breast Cancer 7 (1), 30, 2021 | 45 | 2021 |
| Patient‐reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy AM Hopkins, J Wagner, G Kichenadasse, N Modi, A Rowland, MJ Sorich International Journal of Cancer 147 (11), 3085-3089, 2020 | 35 | 2020 |
| A 10-year update to the principles for clinical trial data sharing by pharmaceutical companies: perspectives based on a decade of literature and policies ND Modi, G Kichenadasse, TC Hoffmann, M Haseloff, JM Logan, ... BMC medicine 21 (1), 400, 2023 | 29 | 2023 |
| Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib ND Modi, AY Abuhelwa, S Badaoui, E Shaw, K Shankaran, RA McKinnon, ... The Breast 58, 57-62, 2021 | 23 | 2021 |
| Generative AI chatbots for reliable cancer information: evaluating web-search, multilingual, and reference capabilities of emerging large language models BD Menz, ND Modi, AY Abuhelwa, W Ruanglertboon, A Vitry, Y Gao, ... European Journal of Cancer 218, 115274, 2025 | 21 | 2025 |
| Audit of data sharing by pharmaceutical companies for anticancer medicines approved by the US Food and Drug Administration ND Modi, AY Abuhelwa, RA McKinnon, AV Boddy, M Haseloff, MD Wiese, ... JAMA oncology 8 (9), 1310-1316, 2022 | 19 | 2022 |
| Heterogeneity and utility of pharmaceutical company sharing of individual-participant data packages AM Hopkins, ND Modi, AY Abuhelwa, G Kichenadasse, NM Kuderer, ... JAMA oncology 9 (12), 1621-1626, 2023 | 18 | 2023 |
| Predicting thrombocytopenia in patients with breast cancer treated with ado-trastuzumab emtansine ND Modi, MJ Sorich, A Rowland, RA McKinnon, B Koczwara, MD Wiese, ... Clinical Breast Cancer 20 (2), e220-e228, 2020 | 17 | 2020 |
| Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancer ND Modi, NO Danell, RNA Perry, AY Abuhelwa, A Rathod, S Badaoui, ... ESMO open 7 (3), 100475, 2022 | 16 | 2022 |
| The influence of pre-existing beta-blockers use on survival outcomes in HER2 positive advanced breast cancer: pooled analysis of clinical trial data ND Modi, JQE Tan, A Rowland, B Koczwara, G Kichenadasse, ... Frontiers in oncology 10, 1130, 2020 | 16 | 2020 |
| Design, synthesis and evaluation of a series of 5-methoxy-2, 3-naphthalimide derivatives as AcrB inhibitors for the reversal of bacterial resistance C Jin, R Alenazy, Y Wang, R Mowla, Y Qin, JQE Tan, ND Modi, X Gu, ... Bioorganic & Medicinal Chemistry Letters 29 (7), 882-889, 2019 | 16 | 2019 |
| A literature review of treatment-specific clinical prediction models in patients with breast cancer ND Modi, MJ Sorich, A Rowland, JM Logan, RA McKinnon, ... Critical Reviews in Oncology/Hematology 148, 102908, 2020 | 15 | 2020 |
| Assessing the system-instruction vulnerabilities of large language models to malicious conversion into health disinformation chatbots ND Modi, BD Menz, AA Awaty, CA Alex, JM Logan, RA McKinnon, ... Annals of Internal Medicine, 2025 | 11 | 2025 |
| The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data. NPJ Breast Cancer 7: 30 ND Modi, JQE Tan, A Rowland, B Koczwara, AY Abuhelwa, ... | 9 | 2021 |
| Association between patient-reported outcomes and survival in patients with advanced urothelial carcinoma treated with atezolizumab E Tan, AY Abuhelwa, S Badaoui, ND Modi, MD Wiese, RA McKinnon, ... Bladder Cancer 8 (1), 81-88, 2022 | 7 | 2022 |
| Clinical Study Report and Individual Participant Data Transparency for US Food and Drug Administration-Approved Anticancer Drugs: A Call for Systematic Data Availability. ND Modi, SM Swain, M Buyse, NM Kuderer, A Rowland, FW Rockhold, ... Journal of Clinical Oncology: Official Journal of the American Society of …, 2024 | 6 | 2024 |
| Accessibility of clinical study reports supporting medicine approvals: a cross-sectional evaluation AM Hopkins, ND Modi, FW Rockhold, T Hoffmann, BD Menz, AA Veroniki, ... Journal of Clinical Epidemiology 167, 111263, 2024 | 5 | 2024 |
Michael SorichProfessor of Clinical Pharmacology, Flinders UniversityVerified email at flinders.edu.au
